Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $WST West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend
EXTON, Pa. , July 25, 2019 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2019 and updated full-year 2019 financial guidance. Second-Quarter 2019 Summary (comparisons to prior-year period) Net ...
Got this from West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend
News: $WST West Announces First-Quarter 2019 Results
EXTON, Pa. , April 25, 2019 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2019 and updated full-year 2019 financial guidance. First-Quarter 2019 Summary (comparisons to prior-year period) Net s...
Got this from https://marketwirenews.com/news-releases/west-announces-first-quarter-2019-results-8055780.html
Exciting market overview provided by West Pharmaceuticals Director of Product Management at SMi's 10th Annual European summit on Pre-Filled Syringes next Jan. Interesting talk on current trends and new tech. http://www.pre-filled-syringes.com/ihub
West Pharmaceutical beats Street 3Q forecasts
October 27, 2016
EXTON, Pa. (AP) _ West Pharmaceutical Services Inc. (WST) on Thursday reported third-quarter earnings of $37.6 million.
On a per-share basis, the Exton, Pennsylvania-based company said it had profit of 50 cents. Earnings, adjusted for restructuring costs and pretax expenses, were 53 cents per share.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 52 cents per share.
The medical device company posted revenue of $376.7 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $372.7 million.
West Pharmaceutical shares have climbed 17 percent since the beginning of the year. The stock has climbed 23 percent in the last 12 months.
West Pharmaceutical upgraded to Outperform from Market Perform at Wells FargoWells Fargo analyst Tim Evans upgraded West Pharmaceutical Services to Outperform saying the company's "strong" quarter provided clear messaging around its margin trajectory. The analyst believes the margin story is now de-risked and he finds the entry point compelling with the stock down 13% from recent highs. Evans keeps an $80-$85 price target range for the shares.
Read more at:
http://thefly.com/landingPageNews.php?id=2452168
Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for West!
Excited to hear more insight from their Director of Global Product Management in Pre-filled Systems and Delivery - Christa Jansen-Otten, when she presents in Central London at Pre-Filled Syringes Europe.
Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub
I live 7 miles from the Clearwater plant This stock has always split when it gets to these prices.The new ceo has made a huge impact look for a long run up
This is the twenty-fourth consecutive annual increase in the Company's dividend
WST INCREASES DIVIDEND BY 8%
http://www.westpharma.com/en/Investors/Pages/NewsReleases.aspx?reqtype=releasetxt&reqid=2201042
Typical WST action.... Market down two days in a row and WST up two days in a row..
West Pharmaceutical Services Inc. (WST) Sets New 12-Month High at $81.80
August 6th, 2016 - 0 comments - Filed Under - by Latisha Jones
West Pharmaceutical Services logoWest Pharmaceutical Services Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $81.80 and last traded at $81.80, with a volume of 97,633 shares traded. The stock had previously closed at $80.96.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a research report on Wednesday, April 20th. Jefferies Group reaffirmed a “hold” rating on shares of West Pharmaceutical Services in a research report on Thursday. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a research report on Friday, May 13th.
West Pharmaceutical Services Inc. (NYSE:WST) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The brokerage presently has a $91.00 target price on the stock. Zacks Investment Research’s target price would suggest a potential upside of 11.66% from the company’s current price
another split coming??
Last two times this stock price topped 60 dollars it split 2 for 1 looks prime for another!!
This has turned out to be BIG for west...
http://www.pharmaasia.com/2015/04/eric-green-is-new-ceo-at-west-pharma/
West now up over 2.5% percent for the day off great quarterly report
$WST DD Notes ~ http://www.ddnotesmaker.com/WST
bullish very long term
$WST recent news/filings
## source: finance.yahoo.com
Thu, 23 Oct 2014 12:52:45 GMT ~ West to Host Third Quarter 2014 Conference Call
[at noodls] - EXTON, PA -- (Marketwired) -- 10/23/14 -- (NYSE: WST) today that it will release third quarter 2014 financial results before the market opens on Thursday, October 30, 2014 and will follow with a conference ...
read full: http://www.noodls.com/view/0BEE0F66A6BFF2C9D7A938147A9B2D3E769763E6
*********************************************************
Thu, 23 Oct 2014 12:00:00 GMT ~ West to Host Third Quarter 2014 Conference Call
[Marketwired] - West Pharmaceutical Services, Inc. today that it will release third quarter 2014 financial results before the market opens on Thursday, October 30, 2014 and will follow with a conference call to discuss ...
read full: http://finance.yahoo.com/news/west-host-third-quarter-2014-120000963.html
*********************************************************
Tue, 21 Oct 2014 12:26:32 GMT ~ West's Vial2Bag DC Device Receives U.S. FDA 510(k) Clearance and CE Mark
[at noodls] - EXTON, Pa., Oct. 21, 2014 /PRNewswire/ -- (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has received 510(k) clearance of the Vial2Bag® DC device from the United ...
read full: http://www.noodls.com/view/D87AD234C5F0952A6D7116757AB79450A33DA934
*********************************************************
Tue, 21 Oct 2014 12:00:00 GMT ~ West's Vial2Bag DC Device Receives U.S. FDA 510(k) Clearance and CE Mark
[PR Newswire] - EXTON, Pa., Oct. 21, 2014 /PRNewswire/ -- West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, has received 510(k) clearance of the Vial2Bag® DC device from the United States Food and Drug Administration, and also the CE Mark for the European Union. The Vial2Bag DC device is produced by West's subsidiary, Medimop Medical Projects Ltd., and is a universal admixture device designed to enable safe, convenient, needle-free reconstitution and transfer of drug products between a vial and a standard IV bag or bottle. Our new Vial2Bag DC device simplifies the IV admixture process and eliminates the risk of needlestick injuries and minimizes potential drug exposure, making this procedure safer and more efficient for healthcare staff," said John Paproski, President, Pharmaceutical Delivery Systems, West Pharmaceutical Services. Progressive Medical Inc. (PMI) will distribute the Vial2Bag DC device to hospitals in the United States.
read full: http://finance.yahoo.com/news/wests-vial2bag-dc-device-receives-120000003.html
*********************************************************
Wed, 15 Oct 2014 14:23:13 GMT ~ West Pharmaceutical Services Warns On FY14, CEO To Retire
read full: http://finance.yahoo.com/news/west-pharmaceutical-services-warns-fy14-142313742.html
*********************************************************
$WST charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$WST company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/WST/company-info
Ticker: $WST
OTC Market Place: Not Available
CIK code: 0000105770
Company name: West Pharmaceutical Services, Inc.
Company website: http://www.westpharma.com
Incorporated In: PA, USA
$WST share structure
## source: otcmarkets.com
Market Value: $3,246,684,941 a/o Oct 27, 2014
Shares Outstanding: 70,764,711 a/o Jun 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 2.05
$WST extra dd links
Company name: West Pharmaceutical Services, Inc.
Company website: http://www.westpharma.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/WST/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/WST/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=WST+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=WST+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=WST+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/WST/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/WST/news - http://finance.yahoo.com/q/h?s=WST+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/WST/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/WST/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/WST/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/WST/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/WST/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/WST/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=WST+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/WST
DTCC (dtcc.com): http://search2.dtcc.com/?q=West+Pharmaceutical+Services%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=West+Pharmaceutical+Services%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=West+Pharmaceutical+Services%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.westpharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.westpharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.westpharma.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/WST/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/WST
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/WST/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/WST/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/WST/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000105770&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/WST/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/WST/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/WST/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/WST/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=WST&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=WST
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/WST/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=WST+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=WST+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=WST
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=WST
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=WST+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/WST/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=WST+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/WST.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=WST
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/WST/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/WST/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/WST/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/WST/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/WST
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/WST
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/WST:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=WST
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=WST
$WST DD Notes ~ http://www.ddnotesmaker.com/WST
~ Thursday! $WST ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $WST ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=WST&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=WST&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=WST
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=WST#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=WST+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=WST
Finviz: http://finviz.com/quote.ashx?t=WST
~ BusyStock: http://busystock.com/i.php?s=WST&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=WST >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
West to Present at Jefferies Conference
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Tuesday 31 May 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the Jefferies 2011 Global Healthcare Conference in New York, NY. Management will present an overview of West's business and outlook on Monday, June 6, 2011 at 4:00 PM ET.
West Announces Third Quarter 2011 Dividend
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Friday 6 May 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors has approved payment of the third-quarter 2011 cash dividend of $0.17 per share. The dividend will be paid on August 3, 2011 to shareholders of record on July 20, 2011
West Announces First Quarter 2011 Results
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Thursday 28 April 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first quarter of 2011. Summary comparative results were as follows:
($ millions, except per-share data )
Three Months Ended
March 31,
2011
2010
Net Sales
$ 295.4
$ 274.7
Gross Profit
88.0
82.2
Reported Operating Profit
28.8
28.9
Adjusted Operating Profit (1)
30.7
29.5
Reported Diluted EPS
$ 0.56
$ 0.57
Adjusted Diluted EPS(1)
$ 0.60
$ 0.58
(1) See "Restructuring and Other Items" section of the release and "Supplemental Information and Notes to Non-GAAP Financial Measures" in the tables following the text of this release.
First-quarter 2011 sales grew 7.5% from the same period last year, or 7.3% excluding the effects of foreign currency translation. Sales increased 8.5% in Pharmaceutical Packaging Systems and 4.7% in Pharmaceutical Delivery Systems. The overall sales mix improved as a result of growing sales of high-value pharmaceutical packaging components and proprietary devices. Contract manufacturing revenues were flat due to scheduled price reductions that offset other gains, and sales of disposable medical device components declined. The Company's order backlog at the end of the quarter was over 11% higher than the comparable amounts at December 31 and March 31, 2010.
West to Host 2011 First Quarter Conference Call
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Friday 22 April 2011
West Pharmaceutical Services, Inc. (NYSE:WST) announced today that it will release 2011 first quarter financial results before the market opens on Thursday, April 28, 2011 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 866-713-8566 (U.S.) or 617-597-5325 (International). The passcode is 44873024
West to Present at Barclays Capital Conference
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Thursday 10 March 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the Barclays Capital 2011 Global Healthcare Conference in Miami, FL. Management will present an overview of West's business and outlook on Wednesday, March 16, 2011 at 4:15 PM ET.
A live audio webcast of the Company's presentation, as well as a copy of the presentation materials, will be accessible from the Company's website at www.westpharma.com/en/investors
The Board also approved payment of the second-quarter 2011 cash dividend of $0.17 per share. The dividend will be paid on May 4, 2011 to shareholders of record on April 20, 2011.
West to Present at UBS Investor Conference
West Pharma (NYSE:WST)
Intraday Stock Chart
Today : Thursday 3 February 2011
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the UBS 21st Annual Global Healthcare Services Conference in New York, NY. Management will present an overview of West's business and outlook on Tuesday, February 8, 2011 at 1:00 PM ET.
Dividend info.Nice trend every quarter
12/16/2010 02/02/2011 0.17 Regular Cash
10/04/2010 11/03/2010 0.17 Regular Cash
05/07/2010 08/04/2010 0.16 Regular Cash
01/22/2010 05/05/2010 0.16 Regular Cash
12/15/2009 02/03/2010 0.16 Regular Cash
10/02/2009 11/04/2009 0.16 Regular Cash
05/06/2009 08/05/2009 0.15 Regular Cash
02/25/2009 05/06/2009 0.15 Regular Cash
12/18/2008 02/04/2009 0.15 Regular Cash
09/22/2008 11/05/2008 0.15 Regular Cash
05/07/2008 08/06/2008 0.14 Regular Cash
02/27/2008 05/07/2008 0.14 Regular Cash
12/14/2007 02/06/2008 0.14 Regular Cash
09/20/2007 11/07/2007 0.14 Regular Cash
07/10/2007 08/01/2007 0.13 Regular Cash
03/14/2007 05/02/2007 0.13 Regular Cash
12/12/2006 02/07/2007 0.13 Regular Cash
09/20/2006 11/01/2006 0.13 Regular Cash
06/27/2006 08/02/2006 0.12 Regular Cash
02/28/2006 05/03/2006 0.12 Regular Cash
12/14/2005 02/01/2006 0.12 Regular Cash
08/16/2005 11/02/2005 0.12 Regular Cash
06/28/2005 08/03/2005 0.11 Regular Cash
03/07/2005 05/04/2005 0.11 Regular Cash
12/14/2004 02/05/2005 0.11 Regular Cash
$42 bucks time to sell
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
95
|
Created
|
04/04/08
|
Type
|
Free
|
Moderators |
http://www.westpharma.com/en/Pages/Default.aspx
http://www.westpharma.com/en/about/Pages/GlobalFacilities.aspx
http://www.pharmaasia.com/2015/04/eric-green-is-new-ceo-at-west-pharma/
-----PLEASE NOTE--------
THIS IS NOT A DAY TRADE STOCK
THIS STOCK HAS AVERAGED 28% PER YEAR FOR 10 YEARS STRAIGHT
2013 2 for 1 stock split
2004 2 for 1 stock split
West Pharmaceutical Services, Inc. manufactures components and systems for injectable drug delivery and plastic packaging, and delivery system components for the healthcare, personal care, and consumer products markets. The company operates in two segments, Pharmaceutical Systems and Tech Group. The Pharmaceutical Systems segment engages in the design, manufacture, and sale of various elastomer, metal, and plastic components used in parenteral drug delivery for the pharmaceutical, generic, and biopharmaceutical industries. It offers various pharmaceutical packaging components, such as stoppers and discs, plungers, seals, dropper bulbs, needle shields and tip caps, and sterile devices. This segment also provides contract analytical laboratory services for testing and evaluating primary drug packaging components. The Tech Group segment produces injection molded components and devices, such as contact lens storage kits, pill dispensers, and disposable blood collection systems for surgical, ophthalmic, diagnostic, and drug delivery systems. This segment also involves in the manufacture and assembly of systems and devices used for nasal, oral, pulmonary, and injectable delivery of drugs used to treat diseases. The company's customers include pharmaceutical, biotechnology, generic drug, and medical-device producers. West Pharmaceutical sells its products primarily in the United States,Asia,Germany,France,and other European countries. It markets its products and services principally through its own sales force and distribution network, as well as through sales agents and distributors. The company was founded in 1923 and is headquartered in Lionville, Pennsylvania.
West Pharmaceutical Services Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Apr-08 is better than 97.2% of S&P 600 companies and 97.9% of Health Care Equipment & Services companies.
Improving Global Healthcare
West helps improve the safe delivery of pharmaceutical, health care and personal care products. Media Relations Contact for North and South America
Second Quarter 2016 Highlights
"Adjusted diluted EPS" and "net sales at constant currency" are Non-GAAP measurements. See discussion under the heading "Non-GAAP Financial Measures" in this release.
Executive Commentary
"We had a successful quarter with solid organic sales growth, increased gross and operating profit margins and new product launches and approvals," said Eric M. Green, President and Chief Executive Officer. "Led by our Commercial group, both the Proprietary Products and Contact-Manufactured Products segments contributed to overall organic sales growth, with broad-based growth in all three market units of Biologics, Generics and Pharma. We continue to see double-digit sales growth in our high-value product offerings including Westar RS® and Westar RU®, Daikyo®, FluroTec® and NovaPure® components."
"We had another strong quarter of gross margin expansion fueled by high-single digit organic sales growth, favorable product mix and operational efficiencies. I am pleased that our Global Operations initiatives are successfully increasing throughput and reducing lead times. As a result, we saw a sequential quarterly reduction in backlog levels and remain on track with our target of achieving faster lead times in the second half of the year and reducing backlog levels that better match underlying demand."
"Earlier this month, the U.S. Food and Drug Administration (FDA) approved the first combination product that incorporates an injectable drug with West's SmartDose® technology for use in the United States. This milestone exemplifies West's strategy of providing the highest quality components and systems to meet our customers' needs for injectable drug delivery solutions; in this case, an integrated containment system that combines the novel SmartDose device with a Daikyo Crystal Zenith® container and a Flurotec® piston. I am proud of the work of our Innovation and Technology team and partners to achieve this milestone. The many years of work and dedication to this project have paved the way for new opportunities for the on-body delivery of injectable drugs."
Mr. Green concluded, "Since the launch of our market-led strategy and business realignment at the start of the year, our teams have performed well, and the company is well positioned for future success. We continue to see solid end-market demand in our Proprietary Products segment and expect to see higher organic sales growth in our Contract-Manufactured Products segment in the second half of the year. With these trends, we are raising our full-year 2016 organic sales growth guidance to a new range of between 7% and 9% and are raising the lower-end of our adjusted diluted EPS guidance
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |